<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00803543</url>
  </required_header>
  <id_info>
    <org_study_id>F080718009</org_study_id>
    <nct_id>NCT00803543</nct_id>
  </id_info>
  <brief_title>Effect of Valacyclovir in the Reduction of HSV-2 Recurrence and Shedding</brief_title>
  <official_title>Seroprevalence of HSV-2 in HIV Infected Subjects and the Effect of Daiy Valacyclovir in the Reduction of HSV-2 Recurrences and Viral Shedding</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine how common herpes is among persons with HIV who do
      not know they have it and if valacyclovir reduces outbreaks of herpes, the amount of HIV in
      the blood, and the amount of HSV in bodily secretions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Most people with herpes infections do not know they have the infection. HSV infections most
      often occur in areas in and around the mouth and genital tract. HSV Type 1 (HSV-1) usually
      causes &quot;cold sores&quot; or fever blisters and HSV Type 2 (HSV-2) usually causes lesions in the
      genital or rectal areas. However, HSV-1 can sometimes cause genital herpes and HSV-2 can
      cause oral lesions (acquired from oral-genital sex). Herpes Simplex is transmitted by contact
      with someone who is shedding virus in either the mouth or genital tract, usually by kissing
      or sexual intercourse. While contact with an active sore can cause transmission, so can
      contact with saliva or genital secretions that are infected, even when the person does not
      have an obvious sore. This is called asymptomatic shedding of HSV. Once acquired, the virus
      has the ability to remain inactive in the nervous system in the area of the mouth or genital
      region.

      Persons with both HIV and HSV-2 often have shedding of both viruses. We know that persons
      with HSV-2 tend to have increased amounts of HIV in their blood as well. Recently, research
      studies have found that taking medicine daily to prevent asymptomatic HSV-2 shedding can
      reduce the amount of HIV found in the blood and in genital secretions. This study seeks to
      determine how common herpes is among persons with HIV who do not know they have it and if
      valacyclovir (FDA approved drug) reduces outbreaks of herpes, the amount of HIV in the blood,
      and the amount of HSV in bodily secretions.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Herpes Simplex Virus Type 2 Recurrence</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Number of recurrences of genital herpes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CD4 Count</measure>
    <time_frame>24 weeks</time_frame>
    <description>CD4 count as measured after 24 weeks of placebo versus valacyclovir. Reports as cells/ml</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With an HIV Viral Load of &lt;500 Copies/ml</measure>
    <time_frame>24 weeks</time_frame>
    <description>Number of participants with an HIV Viral Load of &lt;500 copies/ml at 24 weeks</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of Asymptomatic HSV-2 Genital Shedding</measure>
    <time_frame>24 weeks</time_frame>
    <description>Proportion of days on which HSV shedding was observed. This part of the study was performed in a subset of participants (N = 34). Participant collected daily genital specimens for 8 weeks starting at week 16 and continuing through week 24 of the study.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">103</enrollment>
  <condition>HIV</condition>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Valacyclovir</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This is the arm taking Valacyclovir</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>This is the arm taking the placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valacyclovir</intervention_name>
    <description>500 mg tablets. Dosage two tablets (1000 mg)once daily for 24 weeks</description>
    <arm_group_label>Valacyclovir</arm_group_label>
    <other_name>There are no other names</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Dosage: Two tablets once a day for 24 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>There are no other names</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  19 years or older

          -  HSV-2 (Herpes simplex virus type 2) seropositive as determined by HerpeSelect-2 ELISA

          -  Documented HIV-1 seropositive

          -  Currently receiving HAART for 3 months or longer

          -  CD4 (cluster of differentiation 4) count 350 or greater

          -  Women of child bearing potential must agree to use acceptable contraceptive measures
             during the entire conduct of the study. Acceptable contraceptive methods include one
             or more of the following: oral hormonal contraceptives, injectable hormonal
             contraceptives, transdermal hormonal contraceptives, IUD (intrauterine device),
             diaphragm or cervical cap.

          -  Willing and able to provide written informed consent, undergo clinical evaluations,
             and take study drug as directed

        Exclusion Criteria:

          -  History of symptomatic genital herpes, lesions or symptoms consistent with genital
             herpes, or recurrent undiagnosed symptoms consistent with genital herpes.

          -  Known history of adverse reaction to acyclovir, valacyclovir, or famciclovir.

          -  Planned open label use of acyclovir, valacyclovir, ganciclovir, valganciclovir,
             famciclovir, cidofovir, or foscarnet for oral herpes or other herpes viral infections.

          -  Medical history of seizures

          -  Renal insufficiency, defined as serum creatinine greater than 1.5 mg/dl

          -  AST (aspartate aminotransferase) or ALT (alanine aminotransferase) over 5 times uper
             limit of normal

          -  History of thrombotic microangiopathy

          -  For women, pregnancy as confirmed by a urine or serum pregnancy test.

          -  Any other condition which, in the opinion of the principal investigator, may
             compromise the subject's ability to follow study procedures and complete the study.

          -  Participants with active bacterial STDs (sexually transmitted diseases) may be treated
             and be eligible for enrollment 14 days after STD therapy is discontinued and symptoms
             have resolved.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicholas Van Wagoner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Community Care Building</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 3, 2008</study_first_submitted>
  <study_first_submitted_qc>December 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2008</study_first_posted>
  <results_first_submitted>July 11, 2015</results_first_submitted>
  <results_first_submitted_qc>June 14, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">July 13, 2017</results_first_posted>
  <last_update_submitted>June 14, 2017</last_update_submitted>
  <last_update_submitted_qc>June 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Nicholas Van Wagoner, MD</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>HSV-2</keyword>
  <keyword>Herpes Simplex</keyword>
  <keyword>HSV Type 2</keyword>
  <keyword>HIV</keyword>
  <keyword>HIV/HSV</keyword>
  <keyword>treatment experienced</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valacyclovir</mesh_term>
    <mesh_term>Acyclovir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Valacyclovir</title>
          <description>Valacyclovir: 500 mg tablets. Dosage two tablets (1000 mg)once daily for 24 weeks</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo: Dosage: Two tablets once a day for 24 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="69"/>
                <participants group_id="P2" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Valacyclovir</title>
          <description>Valacyclovir: 500 mg tablets. Dosage two tablets (1000 mg)once daily for 24 weeks</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo: Dosage: Two tablets once a day for 24 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="45"/>
            <count group_id="B2" value="22"/>
            <count group_id="B3" value="67"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45" lower_limit="23" upper_limit="68"/>
                    <measurement group_id="B2" value="43" lower_limit="27" upper_limit="61"/>
                    <measurement group_id="B3" value="45" lower_limit="23" upper_limit="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="67"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Absolute CD4 (cluster of differentiation 4) Count</title>
          <units>cell/ml</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="528" lower_limit="165" upper_limit="1135"/>
                    <measurement group_id="B2" value="693" lower_limit="198" upper_limit="1272"/>
                    <measurement group_id="B3" value="582" lower_limit="165" upper_limit="1272"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number with Undetectable Viral Load</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Herpes Simplex Virus Type 2 Recurrence</title>
        <description>Number of recurrences of genital herpes</description>
        <time_frame>24 Weeks</time_frame>
        <population>No participants reported genital herpes recurrence during the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Valacyclovir</title>
            <description>Valacyclovir: 500 mg tablets. Dosage two tablets (1000 mg)once daily for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Dosage: Two tablets once a day for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Herpes Simplex Virus Type 2 Recurrence</title>
          <description>Number of recurrences of genital herpes</description>
          <population>No participants reported genital herpes recurrence during the study.</population>
          <units>Recurrence</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>CD4 Count</title>
        <description>CD4 count as measured after 24 weeks of placebo versus valacyclovir. Reports as cells/ml</description>
        <time_frame>24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Valacyclovir</title>
            <description>Valacyclovir: 500 mg tablets. Dosage two tablets (1000 mg)once daily for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Dosage: Two tablets once a day for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>CD4 Count</title>
          <description>CD4 count as measured after 24 weeks of placebo versus valacyclovir. Reports as cells/ml</description>
          <units>cells/ml</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="536" lower_limit="191" upper_limit="1112"/>
                    <measurement group_id="O2" value="627.5" lower_limit="199" upper_limit="1268"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With an HIV Viral Load of &lt;500 Copies/ml</title>
        <description>Number of participants with an HIV Viral Load of &lt;500 copies/ml at 24 weeks</description>
        <time_frame>24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Valacyclovir</title>
            <description>Valacyclovir: 500 mg tablets. Dosage two tablets (1000 mg)once daily for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Dosage: Two tablets once a day for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With an HIV Viral Load of &lt;500 Copies/ml</title>
          <description>Number of participants with an HIV Viral Load of &lt;500 copies/ml at 24 weeks</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Rate of Asymptomatic HSV-2 Genital Shedding</title>
        <description>Proportion of days on which HSV shedding was observed. This part of the study was performed in a subset of participants (N = 34). Participant collected daily genital specimens for 8 weeks starting at week 16 and continuing through week 24 of the study.</description>
        <time_frame>24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Valacyclovir</title>
            <description>Valacyclovir: 500 mg tablets. Dosage two tablets (1000 mg)once daily for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Dosage: Two tablets once a day for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Asymptomatic HSV-2 Genital Shedding</title>
          <description>Proportion of days on which HSV shedding was observed. This part of the study was performed in a subset of participants (N = 34). Participant collected daily genital specimens for 8 weeks starting at week 16 and continuing through week 24 of the study.</description>
          <units>Proportion of days</units>
          <param>Number</param>
          <units_analyzed>Total Number of Days Assessed</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Total Number of Days Assessed</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1456"/>
                <count group_id="O2" value="448"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0009"/>
                    <measurement group_id="O2" value="0.0001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Entire study</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Valacyclovir</title>
          <description>Valacyclovir: 500 mg tablets. Dosage two tablets (1000 mg)once daily for 24 weeks</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo: Dosage: Two tablets once a day for 24 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Small populations size. High level of patient withdrawal and loss to follow up.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Nicholas Van Wagoner</name_or_title>
      <organization>University of Alabama at Birmingham</organization>
      <phone>205-934-2840</phone>
      <email>nvw@uab.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

